(Q48567214)

English

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status

scientific article published on 25 April 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

phase II clinical trial

0 references

0 references

author name string

Morris D Groves

1

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Vinay K Puduvalli

2

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Charles A Conrad

3

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Mark R Gilbert

4

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

W K Alfred Yung

5

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Kurt Jaeckle

6

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Vivien Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Kenneth R Hess

8

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Kenneth D Aldape

9

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Victor A Levin

10

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

publication date

25 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

80

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

1

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

83-90

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression

1 reference

https://api.crossref.org/works/10.1007%2FS11060-006-9160-Y

21 January 2018

Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

"...those left behind." Biology and oncology of invasive glioma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dichotomy of astrocytoma migration and proliferation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Migration and invasion in brain neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

https://pubmed.ncbi.nlm.nih.gov/16639492

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-006-9160-Y

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 February 2018

http://europepmc.org/abstract/MED/16639492

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48567214&oldid=2209597773"